PMGC Holdings (ELAB) Gains from Investment Securities (2022 - 2025)
PMGC Holdings (ELAB) posted Gains from Investment Securities of -$214167.0 for Q4 2025, down 154.31% sequentially from $394360.0 in Q4 2024, and down 154.31% YoY from $394360.0 in Q4 2024.
PMGC Holdings (ELAB) Gains from Investment Securities (2022 - 2025) Analysis & Trends
PMGC Holdings has reported Gains from Investment Securities for 4 years, with the latest figure at -$214167.0 in Q4 2025.
- Quarterly Gains from Investment Securities fell 154.31% year-over-year to -$214167.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $87855.0 (up 224.39% YoY) and the FY2025 annual result came in at -$214167.0, down 890.78% from the prior year.
- Gains from Investment Securities fell to -$214167.0 in Q4 2025 per ELAB's latest filing, from $394360.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $29.8 million in Q3 2022 and troughed at -$29.7 million in Q4 2022.
- A 4-year average of -$9369.5 and a median of -$26864.0 in 2024 frame the typical range for Gains from Investment Securities.
- The widest YoY moves for Gains from Investment Securities: up 203.84% in 2024, down 699.24% in 2024.
- Over 4 years, Gains from Investment Securities stood at -$29.7 million in 2022, then jumped by 98.72% to -$379788.0 in 2023, then soared by 203.84% to $394360.0 in 2024, then slumped by 154.31% to -$214167.0 in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$214167.0, $394360.0, and -$65474.0 for Q4 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -214,167.00 |
| Dec 31, 2025 | -214,167.00 |
| Dec 31, 2024 | 394,360.00 |
| Dec 31, 2024 | 394,360.00 |
| Sep 30, 2024 | -65,474.00 |
| Sep 30, 2024 | -65,474.00 |
| Jun 30, 2024 | -26,864.00 |
| Jun 30, 2024 | -26,864.00 |
| Mar 31, 2024 | -274,939.00 |
| Mar 31, 2024 | -274,939.00 |
| Dec 31, 2023 | -379,788.00 |
| Dec 31, 2023 | -379,788.00 |
| Sep 30, 2023 | -8,192.00 |
| Sep 30, 2023 | -8,192.00 |
| Jun 30, 2023 | 222,468.00 |
| Jun 30, 2023 | 222,468.00 |
| Mar 31, 2023 | 236,778.00 |
| Mar 31, 2023 | 236,778.00 |
| Dec 31, 2022 | -29.75 Mn |
| Dec 31, 2022 | -29.75 Mn |